Hematologic Oncology Update What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma
Oct 19, 2023
Dr Toby A Eyre and Dr Brad S Kahl discuss the management of relapsed/refractory mantle cell lymphoma, including treatment options like BTK inhibitors and CAR T-cell therapy, ongoing clinical trials, toxicity analysis of BTK inhibitors, use of MRD in clinical practice, combination treatment, and side effect management.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Introduction
00:00 • 4min
Management of Relapsed/Refractory Mantle Cell Lymphoma
04:27 • 24min
New Trials and Phase 1/2 Data in the Management of Relapsed/Refractory Mantle Cell Lymphoma
28:04 • 5min
Toxicity and Comparative Analysis of BTK Inhibitors in Mantle Cell Lymphoma
32:40 • 4min
Use of MRD in Clinical Practice and Treatment Options for Mantle Cell Lymphoma
36:22 • 12min
Combination Treatment and Side Effect Management
47:59 • 12min
Listener's Experience and Announcement of Upcoming Case Presentation
01:00:00 • 2min